Robin Osterhout
0000-0003-1146-9915
Publication & Citation Trends
Publications
48 total
Seralutinib in adults with pulmonary arterial hypertension (TORREY): a randomised, double-blind, placebo-controlled phase 2 trial
Cited by 56
OpenAlex
Context-dependent activation of STING-interferon signaling by CD11b agonists enhances anti-tumor immunity PDF
Cited by 85
OpenAlex
Pharmacology and Rationale for Seralutinib in the Treatment of Pulmonary Arterial Hypertension OA
Cited by 21
Semantic Scholar
Abstract 5964: Context-dependent induction of interferon signaling by CD11b agonists supports anti-tumor immunity in mouse models and human cancer patients
Cited by 0
Semantic Scholar
Inhaled seralutinib exhibits potent efficacy in models of pulmonary arterial hypertension PDF
Cited by 67
OpenAlex
Results of a phase 2b trial with GB001, a DP2 antagonist, in moderate-to-severe eosinophilic asthma. OA
Cited by 7
Semantic Scholar
An orally bioavailable ENPP1-selective inhibitor demonstrates superior immune preservation effects over STING agonists and confers antitumor efficacy in combination with other therapies in syngeneic tumor models OA
Cited by 3
Semantic Scholar
Randomised clinical trial: a phase 1b study of GB004, an oral HIF‐1α stabiliser, for treatment of ulcerative colitis OA
Cited by 23
Semantic Scholar
Research Topics
Pulmonary Hypertension Research and Treatments
(16)
Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
(8)
Microbial Metabolic Engineering and Bioproduction
(6)
Lung Cancer Treatments and Mutations
(5)
Colorectal Cancer Treatments and Studies
(5)
Affiliations
Genomatica (United States)
Howard Hughes Medical Institute
Max Planck Institute of Colloids and Interfaces
Gossamer Bio (United States)
Ferring Pharmaceuticals (United States)